换一批A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
第一作者：
Julie E,Bauman
第一单位：
Department of Internal Medicine, Division of Hematology/Oncology, University of Pittsburgh, Pittsburgh, PA, USA. baumanje@upmc.edu
作者：
医学主题词
老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤药(Antineoplastic Agents);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);癌, 鳞状细胞(Carcinoma, Squamous Cell);I类磷脂酰肌醇3-激酶类(Class I Phosphatidylinositol 3-Kinases);周期素依赖激酶抑制剂p16(Cyclin-Dependent Kinase Inhibitor p16);细胞因子类(Cytokines);抗药性, 肿瘤(Drug Resistance, Neoplasm);女(雌)性(Female);头颈部肿瘤(Head and Neck Neoplasms);人类(Humans);男(雄)性(Male);中年人(Middle Aged);突变(Mutation);肿瘤复发, 局部(Neoplasm Recurrence, Local);癌基因蛋白质v-akt(Oncogene Protein v-akt);PTEN磷酸水解酶(PTEN Phosphohydrolase);磷酸肌醇3-激酶类(Phosphatidylinositol 3-Kinases);铂(Platinum);蛋白激酶抑制剂(Protein Kinase Inhibitors);原癌基因蛋白质类p21(ras)(Proto-Oncogene Proteins p21(ras));喹唑啉类(Quinazolines);核糖体蛋白质S6激酶类(Ribosomal Protein S6 Kinases);西罗莫司(Sirolimus);存活率(Survival Rate);TOR丝氨酸-苏氨酸激酶(TOR Serine-Threonine Kinases);肿瘤抑制蛋白质类(Tumor Suppressor Proteins)
DOI
10.1016/j.oraloncology.2012.12.016
PMID
23384718
发布时间
2024-10-01
- 浏览6
Oral oncology
461-7页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
